Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC) targeting CD79b. Polivy is the first approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma (DLBCL). Polivy is currently approved in combination with rituximab, cyclophosphamide, doxorubicin and prednisone in more than 95 countries worldwide, including the US and EU, for the treatment of adult patients with previously untreated DLBCL.
Polivy is also approved in combination with bendamustine plus rituximab in more than 100 countries worldwide for the treatment of adults with relapsed or refractory (R/R) DLBCL after one or more prior therapies.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.